| Name | Title | Contact Details |
|---|
Shiru is in the vanguard of startups that are discovering the molecular blueprints of nature — then using new ways to reconstruct the world`s most popular and pleasing ingredients without the need for animals or other unsustainable sources.
NOCION is a biopharmaceutical company that is addressing vexing medical problems head on. We are developing `nocions`—a new kind of therapy that selectively affects actively firing nocioceptors—to provide targeted, robust and sustained relief for the treatment of serious conditions including cough, itch, pain and inflammation.
Azalea Laser and Skin Care is a Wilmington, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Univercells is a technology company offering novel biomanufacturing platforms, aimed at increasing the availability and affordability of biologics – recombinant proteins and vaccines - for all. Univercells designs innovative production processes to significantly decrease the size of the necessary equipment and facility, for a lower capital and operational cost. The company`s process intensification and integration technology entails smaller footprint and unit cost while offering flexible capabilities, from small to large batches. Deployment of affordable production units enables `in-country, for-country` biologics production, creating value for manufacturers and healthcare systems with cost efficiency and local supply while increasing patients` access to healthcare. Univercells was founded in 2013 by experienced entrepreneurs Hugues Bultot, CEO, and José Castillo, CTO, who bring close to 25 years of expertise in the biotechnology and life sciences sectors. Headquartered in Gosselies (Belgium), Univercells benefits from support from the Walloon region, and received €3 million from Takeda in 2015. Most recently, the company was awarded a $12 million grant from the Bill & Melinda Gates Foundation.
GigaGen is advancing a pipeline of first-in-class biotherapeutics, including novel oncology antibody drug combinations and the world`s first recombinant polyclonal hyperimmune gammaglobulin. Behind our diverse and growing pipeline is a mission to bring forth a new generation of highly efficacious drugs, driven by an unparalleled understanding of immune dysregulation. Our proprietary antibody discovery technology quickly characterizes every cell in complex immune systems, powering our selection of drug targets, identification of drug candidates and preclinical assessment of efficacy.